← The Wire
LCTXNYSE
Lineage Cell Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · CA · CIK 876343
Lineage Cell Therapeutics, Inc. develops and commercializes cell therapies for serious unmet medical needs
$317M
Market cap
$1.35
Last close
+5.5%
1D
+7.1%
5D
1.5M
Volume
Price · last 39 sessions-4.9%
May 4L $1.19 · H $1.46Jun 29
490
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KShareholder Vote · Company UpdateJun 12, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 2026DEFA14ADEFA14AApr 29, 2026DEF 14ADEF 14AApr 29, 20268-KCompany UpdateMar 11, 2026424B5424B5Mar 11, 202610-K10-KMar 5, 20268-KResults of OperationsMar 5, 20268-KCompany UpdateNov 28, 20258-KCompany UpdateNov 24, 20258-KCompany UpdateNov 12, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KReg FD Disclosure · Company UpdateAug 26, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KExecutive Change · Shareholder VoteJul 2, 20258-KReg FD Disclosure · Company UpdateJun 23, 2025DEFA14ADEFA14AJun 11, 20258-KAuditor ChangeJun 9, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 20258-KCompany UpdateMay 1, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 202510-K10-KMar 10, 20258-KResults of OperationsMar 10, 20258-KShareholder Vote · Reg FD DisclosureJan 27, 2025DEF 14ADEF 14ADec 9, 2024424B5424B5Nov 21, 20248-KMaterial Agreement · Reg FD DisclosureNov 20, 202410-Q10-QNov 14, 20248-KResults of OperationsNov 14, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 22, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KAuditor ChangeJun 14, 20248-KBylaw Amendment · Shareholder VoteJun 13, 20248-KCompany UpdateMay 14, 2024424B5424B5May 14, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 2024424B5424B5Mar 22, 20248-KMaterial Agreement · Company UpdateMar 22, 202410-K10-KMar 7, 20248-KResults of OperationsMar 7, 20248-KCompany UpdateFeb 15, 2024424B5424B5Feb 6, 20248-KMaterial Agreement · Company UpdateFeb 6, 2024424B5424B5Feb 6, 202410-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KExecutive Change · Shareholder VoteSep 7, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 2023DEFA14ADEFA14AJul 27, 2023DEF 14ADEF 14AJul 27, 20238-KCompany UpdateJun 21, 20238-KCompany UpdateMay 18, 2023424B5424B5May 18, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 202310-K/A10-K/AApr 27, 202310-K10-KMar 9, 20238-KResults of OperationsMar 9, 20238-KReg FD DisclosureJan 23, 202310-Q10-QNov 10, 20228-KResults of OperationsNov 10, 20228-KExecutive ChangeOct 31, 20228-KMaterial Agreement · Equity IssuanceOct 28, 20228-K/AExecutive ChangeSep 30, 20228-KExecutive ChangeSep 26, 202210-Q10-QAug 11, 20228-KResults of OperationsAug 11, 2022SC 13GSC 13GJul 8, 20228-KExecutive ChangeJul 7, 2022
Insider Activity
In the 90 days to Mar 12, 2026: 1 insider bought $24K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 | Culley Brian MPresident and CEO | Buy | 15,000 | $1.63 | $24K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance